Toby Michael Maher

Toby Michael Maher, MD, PhD, is a Clinical Professor of Medicine at the University of Southern California (USC). His research focuses on idiopathic pulmonary fibrosis (IPF), interstitial lung disease, and antifibrotic therapies, with expertise in biomarker discovery, clinical trial design, and genetic susceptibility.

• Affiliation: Keck Medicine of USC, Department of Medicine
• Email: tobymahe@usc.edu

Recent research highlights include advancing machine learning applications in ILD diagnosis, elucidating molecular pathways in fibrosis, and developing predictive biomarker models for treatment response. Publications emphasize phase 2/3 clinical trials (e.g., for BI 1015550, BBT-877) and genetic studies linking telomere biology and HLA variants to IPF risk. His work addresses home monitoring, patient-centered outcomes, and cross-organ fibrosis biology.

He contributes to clinical practice guidelines and precision medicine in fibrotic lung diseases, with a focus on novel therapeutic targets (e.g., autotaxin, LPA1 receptors) and longitudinal disease modeling.